FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379232529> ?p ?o ?g. }

• W4379232529 endingPage "5447" @default.
• W4379232529 startingPage "5425" @default.
• W4379232529 abstract "The approval of CDK4/6 inhibitors has dramatically improved care for the treatment of HR+/HER2- advanced breast cancer, but navigating the rapidly-expanding treatment evidence base is challenging. In this narrative review, we provide best-practice recommendations for the first-line treatment of HR+/HER2- advanced breast cancer in Canada based on relevant literature, clinical guidelines, and our own clinical experience. Due to statistically significant improvements in overall survival and progression-free survival, ribociclib + aromatase inhibitor is our preferred first-line treatment for de novo advanced disease or relapse ≥12 months after completion of adjuvant endocrine therapy and ribociclib or abemaciclib + fulvestrant is our preferred first-line treatment for patients experiencing early relapse. Abemaciclib or palbociclib may be used when alternatives to ribociclib are needed, and endocrine therapy can be used alone in the case of contraindication to CDK4/6 inhibitors or limited life expectancy. Considerations for special populations-including frail and fit elderly patients, as well as those with visceral disease, brain metastases, and oligometastatic disease-are also explored. For monitoring, we recommend an approach across CDK4/6 inhibitors. For mutational testing, we recommend routinely performing ER/PR/HER2 testing to confirm the subtype of advanced disease at the time of progression and to consider ESR1 and PIK3CA testing for select patients. Where possible, engage a multidisciplinary care team to apply evidence in a patient-centric manner." @default.
• W4379232529 created "2023-06-04" @default.
• W4379232529 creator A5022801937 @default.
• W4379232529 creator A5025595526 @default.
• W4379232529 creator A5028603895 @default.
• W4379232529 creator A5047890471 @default.
• W4379232529 creator A5057024351 @default.
• W4379232529 creator A5067468792 @default.
• W4379232529 creator A5070650433 @default.
• W4379232529 creator A5077041865 @default.
• W4379232529 date "2023-06-02" @default.
• W4379232529 modified "2023-09-26" @default.
• W4379232529 title "HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review" @default.
• W4379232529 cites W1839333839 @default.
• W4379232529 cites W1991601194 @default.
• W4379232529 cites W1993837674 @default.
• W4379232529 cites W2107336306 @default.
• W4379232529 cites W2126838184 @default.
• W4379232529 cites W2151082560 @default.
• W4379232529 cites W2153294383 @default.
• W4379232529 cites W2157005154 @default.
• W4379232529 cites W2168397789 @default.
• W4379232529 cites W2290950904 @default.
• W4379232529 cites W2491062142 @default.
• W4379232529 cites W2514365970 @default.
• W4379232529 cites W2528767298 @default.
• W4379232529 cites W2552099557 @default.
• W4379232529 cites W2558360748 @default.
• W4379232529 cites W2560635244 @default.
• W4379232529 cites W2593142478 @default.
• W4379232529 cites W2601260249 @default.
• W4379232529 cites W2620993107 @default.
• W4379232529 cites W2763875663 @default.
• W4379232529 cites W2783718203 @default.
• W4379232529 cites W2794203811 @default.
• W4379232529 cites W2804105316 @default.
• W4379232529 cites W2805575723 @default.
• W4379232529 cites W2896664662 @default.
• W4379232529 cites W2896846857 @default.
• W4379232529 cites W2908699784 @default.
• W4379232529 cites W2923061601 @default.
• W4379232529 cites W2925092419 @default.
• W4379232529 cites W2948069739 @default.
• W4379232529 cites W2972049666 @default.
• W4379232529 cites W2976415870 @default.
• W4379232529 cites W2998603194 @default.
• W4379232529 cites W3010955570 @default.
• W4379232529 cites W3029225363 @default.
• W4379232529 cites W3035496509 @default.
• W4379232529 cites W3043266857 @default.
• W4379232529 cites W3045069873 @default.
• W4379232529 cites W3081828321 @default.
• W4379232529 cites W3133509869 @default.
• W4379232529 cites W3135580847 @default.
• W4379232529 cites W3159931666 @default.
• W4379232529 cites W3165284022 @default.
• W4379232529 cites W3167633519 @default.
• W4379232529 cites W3177478067 @default.
• W4379232529 cites W3178702792 @default.
• W4379232529 cites W3207557929 @default.
• W4379232529 cites W4206666777 @default.
• W4379232529 cites W4211005384 @default.
• W4379232529 cites W4213440051 @default.
• W4379232529 cites W4221085715 @default.
• W4379232529 cites W4226497395 @default.
• W4379232529 cites W4283574464 @default.
• W4379232529 cites W4285719527 @default.
• W4379232529 cites W4293083647 @default.
• W4379232529 cites W4293217929 @default.
• W4379232529 cites W4297984276 @default.
• W4379232529 cites W4297986229 @default.
• W4379232529 cites W4300776185 @default.
• W4379232529 cites W4322769252 @default.
• W4379232529 doi "https://doi.org/10.3390/curroncol30060411" @default.
• W4379232529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37366894" @default.
• W4379232529 hasPublicationYear "2023" @default.
• W4379232529 type Work @default.
• W4379232529 citedByCount "1" @default.
• W4379232529 countsByYear W43792325292023 @default.
• W4379232529 crossrefType "journal-article" @default.
• W4379232529 hasAuthorship W4379232529A5022801937 @default.
• W4379232529 hasAuthorship W4379232529A5025595526 @default.
• W4379232529 hasAuthorship W4379232529A5028603895 @default.
• W4379232529 hasAuthorship W4379232529A5047890471 @default.
• W4379232529 hasAuthorship W4379232529A5057024351 @default.
• W4379232529 hasAuthorship W4379232529A5067468792 @default.
• W4379232529 hasAuthorship W4379232529A5070650433 @default.
• W4379232529 hasAuthorship W4379232529A5077041865 @default.
• W4379232529 hasBestOaLocation W43792325291 @default.
• W4379232529 hasConcept C121608353 @default.
• W4379232529 hasConcept C126322002 @default.
• W4379232529 hasConcept C133925201 @default.
• W4379232529 hasConcept C143998085 @default.
• W4379232529 hasConcept C177713679 @default.
• W4379232529 hasConcept C2775930923 @default.
• W4379232529 hasConcept C2777176818 @default.
• W4379232529 hasConcept C2779134260 @default.
• W4379232529 hasConcept C2779744173 @default.

• next